CPDD 78th Annual Scientific Meeting Program
2016-78th-CPDD-Program-Book-6-07-16FINAL
2016-78th-CPDD-Program-Book-6-07-16FINAL
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Tuesday, June 14<br />
XIII.<br />
WORKSHOPS<br />
Regulatory and methodological considerations in the evaluation of<br />
drug dependence in the preclinical and clinical setting<br />
Chairs: Beatrice Setnik and Michael Klein<br />
Evaluating drug withdrawal effects is an integral component of dependence potential,<br />
which informs the overall safety, appropriate dosing, and scheduling of a drug. The<br />
methodological approaches to assess dependence continue to evolve and require<br />
careful evaluation of both preclinical and clinical data. Physical dependence can<br />
manifest from various drug classes including classes of drugs that are and are not<br />
associated with substance use disorder (e.g. beta blockers, corticosteroids).<br />
Preliminary approaches often include animal models to evaluate psychological<br />
dependence and the physical manifestation of withdrawal type symptoms. Translation<br />
of animal pharmacokinetics to human can be challenging and needs to be carefully<br />
evaluated to determine the translatability of animal to human data. In the clinical<br />
setting, evaluation of withdrawal requires characterization of a drug’s pharmacology to<br />
determine what type of symptoms may manifest upon abrupt discontinuation. Study<br />
populations must be carefully considered, particularly in patient populations that<br />
cannot be safely withdrawn from study drug. Clinical trials must determine what<br />
population, duration of maintenance and endpoints are relevant for a given drug.<br />
Commonly adverse events and drug-specific withdrawal scales are included to evaluate<br />
withdrawal symptoms, however other pharmacodynamics measures may also be<br />
considered. The administration of endpoints and safety monitoring requires also<br />
practical considerations in the context of larger patient trials, where confined stays<br />
may not be possible following abrupt discontinuation. This workshop will address the<br />
regulatory and methodological considerations that are rapidly evolving in this active<br />
area of research and will cover case examples of studies examining drug withdrawal<br />
and dependence.